Are Hemodynamics Surrogate End Points in Pulmonary Arterial Hypertension?

• Published in: Circulation (New York, N.Y.) Vol. 130; no. 9; pp. 768 - 775
• Main Authors: Ventetuolo, Corey E., Gabler, Nicole B., Fritz, Jason S., Smith, K. Akaya, Palevsky, Harold I., Klinger, James R., Halpern, Scott D., Kawut, Steven M.
• Format: Journal Article
• Language: English
• Published: Hagerstown, MD by the American College of Cardiology Foundation and the American Heart Association, Inc 26.08.2014; Lippincott Williams & Wilkins
• Subjects: Adult; Arterial hypertension. Arterial hypotension; Biological and medical sciences; Biomarkers; Blood and lymphatic vessels; Cardiology. Vascular system; Diseases of the peripheral vessels. Diseases of the vena cava. Miscellaneous; Familial Primary Pulmonary Hypertension; Female; Hemodynamics; Humans; Hypertension, Pulmonary - physiopathology; Male; Medical sciences; Middle Aged; Pneumology; Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases; Randomized Controlled Trials as Topic; Hypertension; pulmonary heart disease; Lung disease; Respiratory disease; Lung; hypertension, pulmonary; Cardiovascular disease; Respiratory system; Artery; Pulmonary hypertension; trials; Blood vessel; Heart disease; Clinical trial; End; Circulatory system; Hemodynamics; Cardiology; hemodynamics

BACKGROUND—Although frequently assessed in trials and clinical practice, hemodynamic response to therapy has never been validated as a surrogate end point for clinical events in pulmonary arterial hypertension (PAH). METHODS AND RESULTS—We performed a patient-level pooled analysis of 4 randomized, p...